India to Sri Lanka: Trastuzumab Export Trade Route

The India to Sri Lanka Trastuzumab corridor is one of India's established pharmaceutical export routes, with 15 shipments documented worth a combined $2.0M USD. The route is dominated by BIOCON BIOLOGICS LIMITED, which alone accounts for roughly 62% of all export value, reflecting the consolidated nature of India's trastuzumab manufacturing sector.

Across 7 active suppliers, the average shipment value stands at $131.1K USD — a figure that reflects both bulk commercial orders from large pharmaceutical companies and smaller specialty shipments. Sea freight dominates at 83% of all shipments, consistent with trastuzumab's non-urgent bulk-order profile.

Shipment activity peaks during October–December, with an average transit time of 30 days port-to-port. The route has recorded an annual growth rate of 30.9%, placing it at rank #8 among India's top trastuzumab export destinations globally.

On the import side, key buyers of Indian trastuzumab in Sri Lanka include MEDMART PHARMA (PVT) LTD, BANK OF CEYLON CORPORATE BRANCH , ABC PHARMA SERVICES (PVT) LTD and 6 others. MEDMART PHARMA (PVT) LTD is the single largest importer with 5 shipments valued at $1.2M USD.

India's trastuzumab exports to Sri Lanka are driven primarily by a handful of large-scale manufacturers. BIOCON BIOLOGICS LIMITED with 5 shipments leads the pack, a pattern common in generic pharmaceutical corridors where manufacturing scale creates significant cost advantages. The presence of 7 active exporters signals a competitive but concentrated market — buyers in Sri Lanka benefit from supplier diversity while the top tier handles the majority of volume.

The top 3 suppliers — BIOCON BIOLOGICS LIMITED, BIOCON BIOLOGICS LIMITED , RELIANCE LIFE SCIENCES PRIVATE LIMITED — together account for 99% of total trade value on this route. The average shipment value of $131.1K USD reflects primarily bulk commercial orders from large pharmaceutical distributors.

Beyond the primary product category, shipments on this route include closely related formulations such as canmab 440 mg/vial trastuzumab for injection (rdna origin) 440 mg/vial batch no- bs23005034/bf23003627 and canmab 440 mg/vial trastuzumab for injection (rdna origin) 440 mg/vial batch no- bs23005048/bf23003628, suggesting that buyers in Sri Lanka tend to consolidate orders across related product lines from the same Indian supplier.

On the buying side, MEDMART PHARMA (PVT) LTD is the largest importer with 5 shipments worth $1.2M USD — representing 62% of all trastuzumab imports from India on this route. A total of 9 buyers are active on this corridor.